Description: Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Home Page: www.orexo.com
P.O. Box 303
Uppsala,
751 05
Sweden
Phone:
46 1 87 80 88 00
Officers
| Name | Title |
|---|---|
| Mr. Nikolaj Sorensen | Pres & CEO |
| Mr. Fredrik Jarrsten | Exec. VP & CFO |
| Ms. Cecilia Coupland | Sr. VP & Head of Operations |
| Lena Wange | Investor Relations & Communications Director |
| Mr. Robert Ronn | Sr. VP and Head of R&D |
| Mr. Dennis Urbaniak | Exec. VP of Digital Therapeutics |
| Dr. Edward Kim M.B.A., M.D. | Chief Medical Officer |
| Mr. Robert A. Deluca | Pres of Orexo US Inc |
| Mr. Jesper Lind | Advisor |
Exchange: OTCQX
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 9.2764 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0575 |
| Price-to-Sales TTM: | 1.0027 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 126 |